Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
RLAY
RLAY
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RLAY News
Biotech Stocks Reach New 52-Week Highs
Apr 09 2026
NASDAQ.COM
RELAY THERAPEUTICS INC.: BARCLAYS INCREASES TARGET PRICE FROM $17 TO $21
Apr 08 2026
moomoo
Healthcare Sector Faces Challenges and Opportunities Ahead of Q1 Earnings
Apr 07 2026
seekingalpha
Nextech Invest Increases Stake in Relay Therapeutics
Mar 19 2026
Fool
Nextech Invest Increases Stake in Relay Therapeutics
Mar 19 2026
NASDAQ.COM
Analysis of Growth Drivers in the Biliary Tract Cancer Market
Mar 02 2026
Newsfilter
Casdin Capital Increases Stake in Relay Therapeutics
Feb 27 2026
Fool
Relay Therapeutics Reports 2025 Financial Results and 2026 Milestones
Feb 27 2026
NASDAQ.COM
Relay Therapeutics to Report Q4 and Full Year 2025 Financial Results on February 26
Feb 19 2026
Newsfilter
Relay Therapeutics Executive Large Share Sale Analysis
Feb 06 2026
Fool
Oncolytics Biotech Receives FDA Fast Track Designation
Feb 05 2026
PRnewswire
FDA Accelerates Oncology Drug Approvals, Boosting Market Potential
Feb 05 2026
Newsfilter
Relay Therapeutics Receives FDA Breakthrough Therapy Designation
Feb 03 2026
Newsfilter
Oppenheimer Upgrades Relay Therapeutics Rating
Jan 26 2026
seekingalpha
Oncolytics Biotech Secures FDA Approval with 33% Efficacy for New Drug
Dec 16 2025
Newsfilter
Oncolytics Biotech Secures FDA Approval with 33% Efficacy for Pelareorep in Colorectal Cancer
Dec 16 2025
Globenewswire
Show More News
